A study investigating rimonabant and diet in overweight subjects

Not Applicable

Completed

• Conditions: Overweight and obese subjects at risk of type 2 diabetes; Nutritional, Metabolic, Endocrine; Obesity

• Registration Number: ISRCTN00253207
• Lead Sponsor: Belfast Health and Social Care Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-09-12
• Study Completion: 2010-08-01
• Last Update Posted: 12 February 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Both males and females, age >18 years
2. Body mass index (BMI) >27 kg/m^2; 1. Both males and females, age >18 years
2. Body mass index (BMI) >27 kg/m^2

Exclusion Criteria

1. Pregnant women/ breastfeeding mothers
2. Women of childbearing age unwilling to use appropriate contraception
3. Subjects with history of depression or anxiety
4. Subjects with history of significant cardiac, renal or hepatic dysfunction
5. Subjects concurrently on weight loss medication; 1. Pregnant women/ breastfeeding mothers
2. Women of childbearing age unwilling to use appropriate contraception
3. Subjects with history of depression or anxiety
4. Subjects with history of significant cardiac, renal or hepatic dysfunction
5. Subjects concurrently on weight loss medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The following will be assessed at baseline and 8 weeks (end of interventions):<br>1. Insulin resistance, assessed using the euglycaemic hyperinsulinaemic glucose clamp technique <br>2. Weight;The following will be assessed at baseline and 8 weeks (end of interventions):<br>1. Insulin resistance, assessed using the euglycaemic hyperinsulinaemic glucose clamp technique <br>2. Weight

Secondary Outcome Measures

Name	Time	Method
The following will be assessed at baseline and 8 weeks (end of interventions):<br>1. Meal tolerance tests<br>2. Glycaemic control<br>3. Vascular compliance<br>4. Body composition<br>5. Plasma lipids<br>6. Adipokines<br>7. Fat biopsies;The following will be assessed at baseline and 8 weeks (end of interventions):<br>1. Meal tolerance tests<br>2. Glycaemic control<br>3. Vascular compliance<br>4. Body composition<br>5. Plasma lipids<br>6. Adipokines<br>7. Fat biopsies